Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
79 stopped studies mapped to Infection-Related Malignant Neoplasm and descendants · 82% state a reason
Over the 79 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA… | Phase 1 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT06790966 | Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck…(VERSATILE-003) | Phase 3 | terminated | Jan 24, 2025 | PDS Biotechnology Corp. | The study is being discontinued solely based on financial constraints and is not related to the… | Safety / toxicity |
| NCT07388563 | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | Phase 1 | suspended | Feb 5, 2026 | National Cancer Institute (NCI) | New recruitment on hold for a protocol design amendment/modification. | Enrollment / accrual |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of… | Phase 1 | suspended | May 17, 2022 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral… | Phase 2 | terminated | Aug 9, 2011 | Institut National de la Santé Et de la Recherche Médicale, France | results from interim analysis conducted to study interruption | Efficacy / futility |
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive… | Phase 2 | terminated | Jan 10, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Otsuka Pharmaceutical Co., Ltd. | The study was terminated early due to Sponsor decision, the decision to terminate was not based on… | Safety / toxicity |
| NCT05846724 | Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma(PULSAR) | Phase 2 | withdrawn | May 6, 2023 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | The lack of adequate funding has made it impossible to continue with the clinical study As this… | Funding |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+…(NAVAL-1) | Phase 2 | terminated | Aug 18, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04142398 | Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have… | — | withdrawn | Oct 29, 2019 | AIDS Malignancy Consortium | Closed due to lack of funding. | Funding |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | — | terminated | Jul 6, 2016 | AIDS Malignancy Consortium | Poor accrual | Enrollment / accrual |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | Phase 2 | withdrawn | Nov 8, 2022 | Case Comprehensive Cancer Center | PI left | Investigator |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05831540 | Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in… | N/A | terminated | Apr 26, 2023 | Fred Hutchinson Cancer Center | This study has been terminated due to the conclusion of funding. We were able to collect data on… | Enrollment / accrual |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr… | Phase 1 / Phase 2 | terminated | Dec 7, 2018 | Atara Biotherapeutics | Phase 1B part was completed with review of DLTs and cumulative safety data by Safety Data Review… | Safety / toxicity |
| NCT05882305 | KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial | Early Phase 1 | withdrawn | May 31, 2023 | Kousai Bio Co., Ltd. | No Participants Enrolled | Enrollment / accrual |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 25, 2023 | Nykode Therapeutics ASA | Trial VB-C-04 was stopped due to company strategic reasons and recent changes in standard of care… | Sponsor / business decision |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | Phase 2 | withdrawn | Feb 6, 2018 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | Phase 1 | terminated | May 19, 2021 | Fred Hutchinson Cancer Center | Terminated due to end of funding | Funding |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT04958434 | Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors | Phase 1 | terminated | Jul 12, 2021 | Suzhou Transcenta Therapeutics Co., Ltd. | Corporate Decision | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T… | Phase 2 | terminated | Jun 23, 2011 | Amit Verma | IND withdrawn | Other (stated, no rule matched) |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT01712659 | Ruxolitinib for Adult T-Cell Leukemia | Phase 1 / Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | The adult T-cell leukemia (ATL) research program was terminated after the death of the T-cell… | Investigator |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive… | Phase 1 | withdrawn | Jul 25, 2022 | Pamela Munster | Sponsor funding | Funding |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell… | Phase 1 | withdrawn | Nov 23, 2020 | National Cancer Institute (NCI) | Safety issues with PI3 kinase inhibitors | Safety / toxicity |
| NCT00858793 | High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells… | Phase 1 / Phase 2 | terminated | Mar 10, 2009 | Universitätsklinikum Hamburg-Eppendorf | A leukaemia case was reported in patient treated with a similar vector. For safety risk we stopped… | Safety / toxicity |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT00287495 | BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma | Phase 1 | terminated | Feb 6, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03575234 | Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or… | Phase 1 | withdrawn | Jul 2, 2018 | Emory University | funding and drug were withdrawn | Funding |
| NCT03611205 | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced… | N/A | withdrawn | Aug 2, 2018 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | Phase 1 / Phase 2 | terminated | Dec 19, 2012 | Sheffield Teaching Hospitals NHS Foundation Trust | Poor recruitment | Enrollment / accrual |
| NCT02378922 | Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated… | Phase 1 | withdrawn | Mar 4, 2015 | Fred Hutchinson Cancer Center | Administratively closed prior to subject enrollment | Enrollment / accrual |
| NCT00020683 | A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Cancer Therapy Evaluation Program's (CTEP's) termination of drug supply | Drug supply |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS…(DuRIANS) | Phase 2 | withdrawn | Jul 11, 2017 | Singapore General Hospital | FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds | Other (stated, no rule matched) |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated… | Phase 1 / Phase 2 | withdrawn | Aug 29, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT00686842 | PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma | Phase 1 / Phase 2 | terminated | May 30, 2008 | AIDS Malignancy Consortium | Drug supply unavailable. | Drug supply |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large…(ABC-102) | Phase 1 / Phase 2 | withdrawn | Sep 3, 2014 | RedHill Biopharma Limited | Study was discontinued due to lack of recruitment. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials